EA027831B9 - СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА - Google Patents

СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА

Info

Publication number
EA027831B9
EA027831B9 EA201592283A EA201592283A EA027831B9 EA 027831 B9 EA027831 B9 EA 027831B9 EA 201592283 A EA201592283 A EA 201592283A EA 201592283 A EA201592283 A EA 201592283A EA 027831 B9 EA027831 B9 EA 027831B9
Authority
EA
Eurasian Patent Office
Prior art keywords
oxoandrosta
methylbutyryloxy
carbothioate
ynyl
carbonyloxy
Prior art date
Application number
EA201592283A
Other languages
English (en)
Russian (ru)
Other versions
EA201592283A1 (ru
EA027831B1 (ru
Inventor
Житен Ранчходбхаи Патель
Гопалкумар Чиманлал Патель
Гаурав Сандживкумар Шетх
Санджай Нандлал Мандхане
Читтури Тринадха Рао
Раджаманнар Тхеннати
Original Assignee
Сан Фарма Адвансед Ресёрч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресёрч Компани Лимитед filed Critical Сан Фарма Адвансед Ресёрч Компани Лимитед
Publication of EA201592283A1 publication Critical patent/EA201592283A1/ru
Publication of EA027831B1 publication Critical patent/EA027831B1/ru
Publication of EA027831B9 publication Critical patent/EA027831B9/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EA201592283A 2013-05-28 2014-05-28 СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА EA027831B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (3)

Publication Number Publication Date
EA201592283A1 EA201592283A1 (ru) 2016-04-29
EA027831B1 EA027831B1 (ru) 2017-09-29
EA027831B9 true EA027831B9 (ru) 2017-12-29

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592283A EA027831B9 (ru) 2013-05-28 2014-05-28 СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА

Country Status (18)

Country Link
US (1) US9458187B2 (enExample)
EP (1) EP3004133B1 (enExample)
JP (1) JP6366696B2 (enExample)
KR (1) KR20160030085A (enExample)
CN (1) CN105431445A (enExample)
AU (1) AU2014272640B2 (enExample)
BR (1) BR112015029530A8 (enExample)
CA (1) CA2912400A1 (enExample)
EA (1) EA027831B9 (enExample)
ES (1) ES2664019T3 (enExample)
IL (1) IL242658A0 (enExample)
MX (1) MX2015016283A (enExample)
MY (1) MY179214A (enExample)
PH (1) PH12015502652A1 (enExample)
SG (1) SG11201509680TA (enExample)
UA (1) UA117248C2 (enExample)
WO (1) WO2014192027A1 (enExample)
ZA (1) ZA201508640B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458187B2 (en) 2013-05-28 2016-10-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate
JP2018503667A (ja) 2015-01-31 2018-02-08 スン プハルマ アドバンセド リサーチ カンパニー リミテド S−[4−(3−フルオロ−3−メチルブチリルオキシ)ブタ−2−イニル]6α,9α−ジフルオロ−17α−(フラン−2−イル)カルボニルオキシ−11β−ヒドロキシ−16α−メチル−3−オキソアンドロスタ−1,4−ジエン−17β−カルボチオエートの結晶形態
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
US7208613B2 (en) 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US9458187B2 (en) 2013-05-28 2016-10-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate

Also Published As

Publication number Publication date
EA201592283A1 (ru) 2016-04-29
SG11201509680TA (en) 2015-12-30
IL242658A0 (en) 2016-02-01
EP3004133A1 (en) 2016-04-13
AU2014272640B2 (en) 2018-04-05
MX2015016283A (es) 2016-03-11
ZA201508640B (en) 2017-09-27
PH12015502652A1 (en) 2016-03-07
BR112015029530A2 (pt) 2017-07-25
JP6366696B2 (ja) 2018-08-01
MY179214A (en) 2020-11-02
CA2912400A1 (en) 2014-12-04
BR112015029530A8 (pt) 2019-12-17
KR20160030085A (ko) 2016-03-16
ES2664019T3 (es) 2018-04-18
AU2014272640A1 (en) 2015-11-26
EA027831B1 (ru) 2017-09-29
US20160102117A1 (en) 2016-04-14
UA117248C2 (uk) 2018-07-10
JP2016520122A (ja) 2016-07-11
WO2014192027A1 (en) 2014-12-04
EP3004133B1 (en) 2018-03-07
US9458187B2 (en) 2016-10-04
CN105431445A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
PH12018500981A1 (en) Treatment of osteoarthritis
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
MX375872B (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas.
MX2016002794A (es) Compuestos antiproliferativos.
EA201691649A1 (ru) Способ получения противогрибковых соединений
NZ711192A (en) Process for making benzoxazepin compounds
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
EA201691648A1 (ru) Способ получения противогрибковых соединений
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
EA201690763A1 (ru) Лечение рака поджелудочной железы
IN2014MU00675A (enExample)
UA113988C2 (xx) Спосіб стабілізації бета-напівгідрату штукатурного гіпсу
EA027831B9 (ru) СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA201591449A1 (ru) Способы получения противораковых композиций
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
IN2013MU01290A (enExample)
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.
PH12017501360A1 (en) Crystalline form of s-(4-3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(fluran-2-yl) carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate
MX2015017747A (es) Proceso para producir 2-fenil-1, 3-benzoxazoles.
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
IN2013CH05982A (enExample)
IN2013MU02771A (enExample)

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU